Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-9966
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities ; volume:37 ; number:1 ; day:13 ; month:3 ; year:2018 ; pages:1-10 ; date:12.2018
Journal of experimental & clinical cancer research ; 37, Heft 1 (13.3.2018), 1-10, 12.2018
- Urheber
-
Porru, Manuela
- Beteiligte Personen und Organisationen
-
Pompili, Luca
Caruso, Carla
Biroccio, Annamaria
Leonetti, Carlo
SpringerLink (Online service)
- DOI
-
10.1186/s13046-018-0719-1
- URN
-
urn:nbn:de:1111-201805172262
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:50 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Porru, Manuela
- Pompili, Luca
- Caruso, Carla
- Biroccio, Annamaria
- Leonetti, Carlo
- SpringerLink (Online service)
Ähnliche Objekte (12)
Advances in KRAS mutation inhibition in metastatic colorectal cancer
Targeting Myc-driven stress vulnerability in mutant KRAS colorectal cancer
Targeting of SLC25A22 boosts the immunotherapeutic response in KRAS-mutant colorectal cancer
Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories
Colorectal cancer with KRAS mutation
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer
KRAS mutation analysis of single circulating tumor cells from patients with metastatic colorectal cancer
Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer
KRAS mutations: variable incidences in a Brazilian cohort of 8,234 metastatic colorectal cancer patients
The pattern of KRAS mutations in metastatic colorectal cancer: a retrospective audit from Sri Lanka
KRAS Status is Associated with Metabolic Parameters in Metastatic Colorectal Cancer According to Primary Tumour Location
Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy
Advances in KRAS mutation inhibition in metastatic colorectal cancer
Targeting Myc-driven stress vulnerability in mutant KRAS colorectal cancer
Targeting of SLC25A22 boosts the immunotherapeutic response in KRAS-mutant colorectal cancer
Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories
Colorectal cancer with KRAS mutation
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer
KRAS mutation analysis of single circulating tumor cells from patients with metastatic colorectal cancer
Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer
KRAS mutations: variable incidences in a Brazilian cohort of 8,234 metastatic colorectal cancer patients
The pattern of KRAS mutations in metastatic colorectal cancer: a retrospective audit from Sri Lanka
KRAS Status is Associated with Metabolic Parameters in Metastatic Colorectal Cancer According to Primary Tumour Location
Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy
Advances in KRAS mutation inhibition in metastatic colorectal cancer
Targeting Myc-driven stress vulnerability in mutant KRAS colorectal cancer
Targeting of SLC25A22 boosts the immunotherapeutic response in KRAS-mutant colorectal cancer
Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories
Colorectal cancer with KRAS mutation
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer
KRAS mutation analysis of single circulating tumor cells from patients with metastatic colorectal cancer
Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer
KRAS mutations: variable incidences in a Brazilian cohort of 8,234 metastatic colorectal cancer patients
The pattern of KRAS mutations in metastatic colorectal cancer: a retrospective audit from Sri Lanka
KRAS Status is Associated with Metabolic Parameters in Metastatic Colorectal Cancer According to Primary Tumour Location